High Incidence and Prevalence Rate of Breast Cancer Worldwide
Breast cancer is known to be the most common form of cancer in women, around the world. It is a common misconception that breast cancer is regarded as a disease of the developed world. Statistics say that around 50% of breast cancer cases and more than 58% of deaths occur in less developed countries. The National Cancer Institute has estimated that 246,660 cases of breast cancer were diagnosed in 2016. The high incidence and prevalence rate show that the breast cancer therapeutics market will boost over the forecast period. Today, increasing number of countries are adopting early cancer detection programs, around the world. If these initiatives continue, the demand for breast cancer therapeutics is bound to increase, with most of the cases being detected in the early stages. Along with the other factors, such as high investments on R&D, and the advancements in cancer biology and pharmacology promoting drug development, are driving the market.
Risk of Adverse Effects of Radiation Exposure
Radiation plays an important role in the treatment of breast cancer, especially in the later stages of diagnosis, by destroying cancer cells in the breast that may stick around after surgery. However, radiation therapy is not always good for one’s health. Extended exposure to radio waves can cause adverse side effects to the patient. Exposure to radiations can have varying effects, depending on the levels of radiation the patient is exposed to. Internal exposure can sometimes cause deposition of certain elements in bones or organs. For acute exposures, initial physical effects can be seen at around 25-50 rem. Radiations, as strong as 150-350 rem, can cause nausea, fatigue, and skin reddening. These adverse effects of radiation are decreasing the market, as it is creating fear among people. High competition among the market players is impacting the growth of the breast cancer therapy market.
North America to Dominate the Market
North America dominates the market for breast cancer therapy, due to the fact that the prevalence of breast cancer is on the rise in this region, along with an increase in R&D funding through public and private sectors. Asia-Pacific region is expected to grow at a significant pace, over the forecast period.
Key Developments in the Market
- January 2018: U.S. FDA approved expanded use of AstraZeneca cancer drug, Lynparza.
- November 2017: Bayer signed a partnership with cancer drug maker Loxo.
Reasons to Purchase the Report
- Current and future market outlook for breast cancer therapy in the developed and emerging markets
- Analyze various perspectives on the market, with the help of Porter’s five forces analysis
- The segment that is expected to dominate the market
- Regions that are expected to witness the fastest growth, during the forecast period
- Identify the latest developments, market shares, and strategies employed by the major market players.
- 3-month analyst support, along with the market estimate sheet (in excel).
This report can be customized to meet your requirements. Please contact us for more information.
1.1 Market Definition
2. Research Methodology
3. Executive Summary
4. Key Inferences
5. Market Overview
5.1 Current Market Scenario
5.2 Porter's Five Forces Analysis
5.2.1 Bargaining Power of Suppliers
5.2.2 Bargaining Power of Consumers
5.2.3 Threat of New Entrants
5.2.4 Threat of Substitute Products and Services
5.2.5 Competitive Rivalry within the Industry
6. Drivers, Restraints, Opportunities and Challenges Analysis (DROC)
6.1 Market Drivers
6.1.1 High Incidence and Prevalence Rate of Breast Cancer Worldwide
6.1.2 Increasing Investments on R&D
6.1.3 Advancements in Cancer Biology & Pharmacology Promoting Drug Development
6.2 Market Restraints
6.2.1 Risk of Adverse Effects of Radiation Exposure
6.2.2 High Degree of Competition among Market Players
6.4 Key Challenges
7. Market Segmentation
7.1 Segmentation -By Therapy
7.1.1 Radiation Therapy
7.1.2 Targeted therapy
18.104.22.168 Tykerb (Lapatinib)
7.1.3 Hormonal therapy
22.214.171.124 Selective Estrogen - Receptor Modulators
126.96.36.199 Aromatase Inhibitors
188.8.131.52 Alkylating agents
7.2 Segmentation - By Geography
7.2.1 North America
184.108.40.206 United States
220.127.116.11 United Kingdom
18.104.22.168 Rest of Europe
22.214.171.124 New Zealand
126.96.36.199 South Korea
188.8.131.52 Rest of Asia-Pacific
7.2.4 Middle East & Africa
184.108.40.206 South Africa
220.127.116.11 Rest of Middle East & Africa
7.2.5 South America
18.104.22.168 Rest of South America
8. Competitive Landscape
8.1 Mergers and Acquisition Analysis
8.2 Agreements, Collaborations, and Partnerships
8.3 New Product Launches
9. Key Players
9.3 Beckman Coulter
9.4 Bristol Myer Squibb
9.6 Merck & Co.
10. Future of the Market